0001714899-22-000035.txt : 20220211 0001714899-22-000035.hdr.sgml : 20220211 20220211171921 ACCESSION NUMBER: 0001714899-22-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220209 FILED AS OF DATE: 20220211 DATE AS OF CHANGE: 20220211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Watts Ryan J. CENTRAL INDEX KEY: 0001724310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 22622773 MAIL ADDRESS: STREET 1: C/O DENALI THERAPEUTICS INC. STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wf-form4_164461792855991.xml FORM 4 X0306 4 2022-02-09 0 0001714899 Denali Therapeutics Inc. DNLI 0001724310 Watts Ryan J. C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2022-02-09 4 S 0 2719 37.5519 D 2119442 I See footnote Common Stock 2022-02-10 4 M 0 64631 5.28 A 254522 D Common Stock 2022-02-10 4 M 0 6118 9.60 A 260640 D Stock Option (right to buy) 5.28 2022-02-10 4 M 0 64631 0 D 2027-03-07 Common Stock 64631.0 0 D Stock Option (right to buy) 9.6 2022-02-10 4 M 0 6118 0 D 2027-08-21 Common Stock 6118.0 0 D Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $37.51 to $37.745 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 8800 restricted stock units held by the Reporting Person. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Includes 189,891 restricted stock units. The shares subject to the option were fully vested and exercisable. /s/ Tyler Nielsen, by power of attorney 2022-02-11 EX-24 2 poa.htm POWER OF ATTORNEY FOR: /S/ TYLER NIELSEN, BY POWER OF ATTORNEY 
POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Denali Therapeutics Inc. (the "Company"), hereby constitutes and appoints Ryan J. Watts, Steve E. Krognes, Alexander Schuth and Tyler Nielsen, and each of them, as the undersigned's true and lawful attorney-in-fact to:

1.    complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

2.    do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of February, 2022.

Signature,
Print Name:  =Erik Harris